A 48-year-old man with a 6-week history of recurrent oral ulcers and progressive blistering of the chest and axillae presents to the dermatology clinic. Serum testing reveals circulating IgG antibodies against desmoglein-3. Histopathology confirms suprabasal acantholysis. The patient is started on systemic corticosteroids. Which of the following is the most appropriate additional therapeutic agent to achieve steroid-sparing effect and long-term disease control?

Explanation

## Steroid-Sparing Agents in Pemphigus Vulgaris ### Treatment Strategy **Key Point:** Systemic corticosteroids are the first-line treatment for pemphigus vulgaris, but steroid-sparing agents are added early to minimize long-term glucocorticoid toxicity and achieve remission. **High-Yield:** Azathioprine and mycophenolate mofetil (MMF) are the gold-standard steroid-sparing agents in pemphigus vulgaris. ### Mechanism of Steroid-Sparing Agents | Agent | Mechanism | Efficacy in PV | Onset | | --- | --- | --- | --- | | **Azathioprine** | Purine antagonist; inhibits T-cell proliferation | Excellent steroid-sparing effect | 4–8 weeks | | **Mycophenolate Mofetil** | Selective IMPDH inhibitor; reduces B and T cell proliferation | Excellent; preferred in some centers | 2–4 weeks | | **Dapsone** | Antimicrobial + immunomodulatory | Effective in pemphigus foliaceus, limited in PV | 1–2 weeks | | **Methotrexate** | Antimetabolite; inhibits folate metabolism | Moderate; not preferred as first-line steroid-sparer | 4–6 weeks | **Clinical Pearl:** Azathioprine and MMF are preferred because they directly suppress B-cell and T-cell responses, reducing pathogenic anti-desmoglein antibody production and achieving sustained remission. ### Typical Treatment Algorithm ```mermaid flowchart TD A[Pemphigus Vulgaris Diagnosed]:::outcome --> B[Systemic Corticosteroids]:::action B --> C[Add Steroid-Sparer at Diagnosis]:::action C --> D{Agent Choice}:::decision D -->|First-line| E[Azathioprine or MMF]:::action D -->|Alternative| F[Dapsone or Methotrexate]:::action E --> G[Taper steroids over months]:::action F --> G G --> H[Maintain remission on steroid-sparer alone]:::outcome ``` ### Dosing & Monitoring - **Azathioprine:** 1–2 mg/kg/day; monitor CBC, LFTs (risk of myelosuppression, hepatotoxicity) - **MMF:** 1–3 g/day in divided doses; monitor CBC, renal function - **Dapsone:** 50–100 mg/day; monitor for hemolysis and methemoglobinemia (especially in G6PD deficiency) **Warning:** Dapsone is less effective in pemphigus vulgaris (better for pemphigus foliaceus) and has a narrower therapeutic window. ### Why Topical Agents Are Insufficient **Key Point:** Topical tacrolimus alone cannot suppress systemic autoimmunity and anti-desmoglein antibody production; it is adjunctive only for oral lesions. [cite:Harrison 21e Ch 297]